Arius Research, Inc. and Takeda Pharmaceutical Co. have entered into a three-year, multi-product collaboration using Arius’ FunctionFIRST Platform to discover treatments for human disease. Under the terms of the agreement, Arius will receive an upfront technology access fee of $2 million, consisting of $1 million each in cash and equity investment respectively, and research funding for the three years. Arius will also be entitled to milestone payments based on clinical progress plus royalt...